Corvus Pharmaceuticals (CRVS) Stock: Buy, Sell, or Hold?
CRVS - Corvus Pharmaceuticals, Inc.
$10.90
-0.03 (-0.27%)
▼
5d:
-6.2%
30d:
-23.24%
90d:
-28.15%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 03, 2026
29d
Get Alerted When CRVS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CRVS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CRVS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CRVS is currently trading at $10.90, which is considered oversold relative to its 30-day fair value range of $11.90 to $14.24.
Technical Outlook: Technically, CRVS is showing sideways momentum. The price is currently testing key support at $10.64. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CRVS scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $33.14 (+204.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRVS is showing sideways momentum. The price is currently testing key support at $10.64. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CRVS scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $33.14 (+204.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$11.90 -
$14.24
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
Protect Your Profits
Holding CRVS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 204.1% below Wall St target ($33.14)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$11.90 -
$14.24
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$10.64
Resistance Level
$13.46
Current Trend
Sideways
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.21
Wall Street Target
$33.14
(+204.1%)
Share & Embed Analysis
Last updated: October 03, 2026 8:46 PM ET
Data refreshes hourly during market hours. Next update: 9:46 PM
Data refreshes hourly during market hours. Next update: 9:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRVS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 55 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 54 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 66 BUY |
Advanced CRVS Option Strategies
Professional options setups generated by AI based on today's CRVS price and gamma walls.
